retatrutide clinical trial results weight loss Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial loss. Read about the work via the link in the comments First Retatrutide phase 3 data,

Therefore, the practice of microdosing GLP-1 medications is experimental and off-label and is not approved by the FDA

The recently developed receptor agonists for glucagon-like peptide-1 (GLP-1RAs), stimulate insulin secretion and reduce glycated hemoglobin levels without having side effects such as weight gain and hypoglycemia

2001 showed ipamorelin at 100 g/kg three times daily subcutaneously for three months counteracted glucocorticoid-induced bone loss in rats, with periosteal bone formation rate increasing 4-fold versus glucocorticoid alone

pancreatitis PRR 2.2x lower)

They need to be prescribed appropriately, with tailored wraparound support alongside them, to ensure people can fully benefit and maintain weight loss for as long as possible when they stop taking the medication. More on GLP-1s: Something Grim Is Happening to People Who Go Off GLP-1s